Advertisement

Picture EBD Group BioTech Showcase 2022 For Investors 650x100

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in North America, Europe and Israel or involving organisations from these countries.

Total search results: 5370 | Ordered by Date (descending)
1 2 3 ... 52 53 54  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
ProtaGene–Ampersand: investment, 202201 existent portfolio company after merger/acquisition of PPS GmbH + BioAnalytix + GeneWerk GmbH in 7/21 2022-01-12
Rockefeller Univ–Lumicks: microscope, 202201 supply of Quadrupole C-Trap system to lab of Prof Michael O’Donnell 2022-01-12
Scitara–Flybridge Capital: investment, 202201 financing round Series B totalling $15m incl existing + co-investor Flybridge Capital 2022-01-11
Scitara–Northpond Ventures: investment, 202201 financing round Series B totalling $15m incl existing + lead investor Northpond Ventures 2022-01-11
Scitara–Scott Partnership: public relations, 202201 service existent by Scott PR 2022-01-11
Scitara–SEVERAL: investment, 202201 financing round Series B $15m led by Northpond Ventures 2022-01-11
Exelead–Merck (DE): investment, 202201– acquisition $760m in cash by Merck ANNOUNCED 2022-01-06
BioNTech–Pfizer: investment, 202201 equitiy investment $150m by Pfizer in connection with shingles vaccine collaboration 2022-01-05
Pfizer–BioNTech: mRNA-based vaccines, 202201– collab developm $50m net cash upfront shingles vaccine with shared development cost + profits 2022-01-05
PhoreMost–Polaris Quantum Biotech: cancer drug discovery, 202201– collab r+d using Tachyon quantum computing platform with Siteseeker platform 2022-01-05
Sound Bioventures–Denmark (govt): investment, 202201 1st closing of 1st fund totalling €110m incl investor Vćkstfonden 2022-01-04
Sound Bioventures–EU (govt): investment, 202201 1st closing of 1st fund totalling €110m incl investor EIF unde EGF 2022-01-04
Sound Bioventures–Novo Group: investment, 202201 1st closing of 1st fund totalling €110m incl investor Novo Holdings 2022-01-04
Sound Bioventures–PERSON: investment, 202201 1st closing of 1st fund totalling €110m incl founding partners C Breum + J Kördel + B Mukhopadhyay 2022-01-04
Sound Bioventures–Ramsbury Invest: investment, 202201 1st closing of 1st fund totalling €110m incl investor Ramsbury Invest 2022-01-04
Sound Bioventures–SEVERAL: investment, 202201 first closing of €110m Sound Bioventures Fund I AB 2022-01-04
Sound Bioventures–Sweden (govt): investment, 202201 1st closing of 1st fund totalling €110m incl investor Saminvest 2022-01-04
Ortho Clinical Diagnostics–Quidel: investment, 202112– acquisition merger $1.75b in cash + $4.25b in shares results in 38% onwership for Ortho owners 2021-12-23
Personal Genome Diagnostics–LabCorp: investment, 202112– acquisiton of PGDx for $450m cash at closing + $125m milestones ANNOUNCED 2021-12-23
Sorriso Pharmaceuticals–Arix Bioscience: investment, 202112 financing round Series A totalling $31m incl $13m (26%stake) from co-lead investor Arix 2021-12-22
Sorriso Pharmaceuticals–New Enterprise Associates: investment, 202112 financing round Series A totalling $31m incl co-lead investor NEA 2021-12-22
Sorriso Pharmaceuticals–SEVERAL: investment, 202112 financing round Series A $31m co-led by NEA + Arix Bioscience plc 2021-12-22
Amunix Pharmaceuticals–Sanofi: investment, 202112– acquisition $1b upfront + $225m milestones ANNOUNCED 2021-12-21
Protein Metrics–Insightful Science: investment, 202112 acquisition of Protein Metrics by Insightful Science 2021-12-21
Chord Therapeutics–Merck (DE): investment, 202112– acquisition of Chord by Merck KGaA from sole investor Omega Funds 2021-12-20
Genenta Science–LifeSci: public relations, 202112 service existent IR by LifeSci Advisors 2021-12-17
Genenta Science–SEVERAL: investment, 202112 direct offering $8.28m of 720.1k ordinary shares for subscription by exisiting shareholders at $11.5/share 2021-12-17
NorthSea Therapeutics–Hercules Capital: investment, 202112 financing round Series C totalling $80m incl new + co-investor Hercules Capital 2021-12-17
NorthSea Therapeutics–New Science Ventures: investment, 202112 financing round Series C totalling $80m incl existing + co-investor New Science 2021-12-17
NorthSea Therapeutics–OTHER: investment, 202112 financing round Series C totalling $80m incl new + co-investor large managed care organisation 2021-12-17
NorthSea Therapeutics–SEVERAL: investment, 202112 financing round Series C $80m co-led by Ysios Capital + Forbion Growth 2021-12-17
NorthSea Therapeutics–Sofinnova: investment, 202112 financing round Series C totalling $80m incl existing + co-investor Sofinnova 2021-12-17
NorthSea Therapeutics–VenBio: investment, 202112 financing round Series C totalling $80m incl existing + co-investor VenBio 2021-12-17
Anaveon–Cowen: investment, 202112 financing round Series B totalling CHF110m incl new + co-investor Cowen Healthcare Investments 2021-12-16
Anaveon–Pfizer: investment, 202112 financing round Series B totalling CHF110m incl new + co-investor Pifzer Ventures 2021-12-16
Anaveon–Pontifax: investment, 202112 financing round Series B totalling CHF110m incl new + co-investor Pontifax 2021-12-16
Anaveon–SEVERAL: investment, 202112 financing round Series B CHF110m with new + lead investor Forbion 2021-12-16
Argobio–GeneCode: GDNF mimetics, 202112– collab development with up to €3m funding for incubation phase by Argobio to incorporate new biotech company 2021-12-16
Biosero–Bico: investment, 202112– acquisition up to $165m in cash + shares by Bico 2021-12-16
Evotec–Gates Foundation: grant, 202112– grant $18m for drug r+d in area of women’s health + contraceptive technology 2021-12-16
Depixus–Casdin Capital: investment, 202112 financing round Series A totalling €30.6m incl new + co-investor Casdin Capital 2021-12-15
Depixus–SEVERAL: investment, 202112 financing round Series A €30.6m co-led by Lansdowne Partners + PSIM Fund (Bpifrance) 2021-12-15
Lonza–Agilent: analytical instruments, 202112– strategic alliance to integrate analytical technologies in Cocoon cell therapy production platform 2021-12-15
Biogazelle–CellCarta: investment, 202112 acquisition of Biogazelle by CellCarta 2021-12-14
BMS–Immatics: TCR Bispecific, 202112– license ww excl $150m upfront + $770m milestones + royalties to IMA401 programme 2021-12-14
Ryvu Therapeutics–LifeSci: public relations, 202112 service existent IR by LifeSci Advisors 2021-12-14
Sirius Medical–SEVERAL: investment, 202112 financing round Series A 2nd closing €na with BOM Brabant Ventures + Holland Capital et al 2021-12-14
Vifor Pharma–CSL: investment, 202112– cash tender offer CHF10.9b ($11.7b) at CHF167/share ANNOUNCED 2021-12-14
Arena Pharmaceuticals–Pfizer: investment, 202112– acquisition $6.7b in cash at $100/share by Pfizer ANNOUNCED 2021-12-13
deepCDR Biologics–Alloy Therapeutics: investment, 202112 acquisition of deepCDR Biologics by Alloy 2021-12-09
Forbion European Acquisition Corporation–SEVERAL: investment, 202112 SPAC US IPO $110m with 11m units at $10/unit 2021-12-09
Aleph Farms–Wacker: cell culture media, 202112– collab developm production process for growth-medium proteins for cultured meat 2021-12-08
Merck (DE)–Merck (DE): investment, 202112 third increase of financial commitment by €600m in evergreen corporate venture fund M Ventures 2021-12-08
Adendra Therapeutics–Apple Tree Partners: investment, 202112 founding Series A investment Ł40m from ATP Life Sciences UK 2021-12-07
Emergence Therapeutics–SEVERAL: investment, 202112 financing round Series A €87m led by Pontifax Venture Capital 2021-12-07
Freenome–HBM: investment, 202112 financing round Series D totalling $300m incl new + co-investor HBM Healthcare Investments 2021-12-07
Freenome–Novartis: investment, 202112 financing round Series D totalling $300m incl existing + co-investor Novartis 2021-12-07
Freenome–Perceptive Advisors: investment, 202112 financing round Series D totalling $300m incl co-lead investor Perceptive Advisors 2021-12-07
Freenome–RA Capital: investment, 202112 financing round Series D totalling $300m incl existing + co-lead investor RA Capital Management 2021-12-07
Freenome–Roche: investment, 202112 financing round Series D totalling $300m incl existing + co-investor Roche Venture Fund 2021-12-07
Freenome–SEVERAL: investment, 202112 financing round Series D $300m co-led by Perceptive Advisors + RA Capital Management 2021-12-07
Freenome–Siemens: breast cancer diagnostics, 202112– collab research using imaging + multi-omics to identify markers for early detection 2021-12-07
Odyssey Therapeutics–HBM: investment, 202112 financing round Series A totalling $218m incl co-investor HBM Healthcare Investments 2021-12-07
Odyssey Therapeutics–OrbiMed: investment, 202112 financing round Series A totalling $218m incl lead investor OrbiMed Advisors 2021-12-07
Odyssey Therapeutics–SEVERAL: investment, 202112 financing round Series A $218m led by OrbiMed Advisors + co-led by SR One 2021-12-07
Odyssey Therapeutics–SR One: investment, 202112 financing round Series A totalling $218m incl co-lead investor SR One Capital Management 2021-12-07
Quay Pharmaceuticals–SGS: investment, 202112 acquisition of Quay Pharma by SGS 2021-12-07
Roche–Recursion Pharmaceuticals: AI-based drug discovery, 202112– strategic collab $150m upfront up to 40 programs to be selected by Roche+Genentech 2021-12-07
Bayer–Recursion Pharmaceuticals: AI-based drug discovery, 202112– strategic collab expansion to include inferential search capabilities 2021-12-06
AviadoBio–SEVERAL: investment, 202112 financing round Series A Ł58.6m led by NEA + co-led by Monograph Capital 2021-12-03
EUSA Pharma–Recordati: investment, 202112– acquisition €750m of EUSA Pharma UK Ltd from EW Healthcare Partners 2021-12-03
Integra Therapeutics–SEVERAL: investment, 202112 seed financing round €4.5m with Advent FB + Invivo Capital + Takeda Ventures 2021-12-02
Integra Therapeutics–Takeda: investment, 202112 seed financing round totalling €4.5m incl investor Takeda Ventures 2021-12-02
Novartis–UCB: Parkinson drugs, 202112– collab up to $1.5b with $150m upfront ww developm + commercialisation of UCB0599 + option for UCB7853 2021-12-02
Sixfold Bioscience–SEVERAL: investment, 202112 seed financing round 2nd closing $2.2m bringing total of dilutive + non-elutive funding to $10.5m 2021-12-02
SciRhom–SEVERAL: investment, 202111 seed financing round extension €8m bringing total funding to €16m 2021-11-30
Ablaze Pharmaceuticals–RayzeBio: radiopharmaceuticals, 202111c– license excl developm + commercialisation to series of products in Greater China 2021-11-29
Ablaze Pharmaceuticals–SEVERAL: investment, 202111 financing round Series A $75m co-led by Vivo Capital + AdvanTech Capital 2021-11-29
HotSpot Therapeutics–Life Sciences Partners: investment, 202111 financing round Series C totalling $100m incl new + significant co-investor LSP 2021-11-29
HotSpot Therapeutics–SEVERAL: investment, 202111 financing round Series C $100m led by Pivotal BioVenture Partners 2021-11-29
HotSpot Therapeutics–Sofinnova: investment, 202111 financing round Series C totalling $100m incl existing + co-investor Sofinnova Partners 2021-11-29
Lengo Therapeutics–Blueprint Medicines: investment, 202111– acquisition $250m cash upfront + $215m milestones SIGNED 2021-11-29
Quell Therapeutics–SEVERAL: investment, 202111 financing round Series B $156m co-led by Jeito + Ridgeback Capital + SV Health Investors + Fidelity 2021-11-29
Allorion Therapeutics–Qiming: investment, 202111 financing round Series A totalling $40m incl lead investor Qiming Venture Partners 2021-11-24
Allorion Therapeutics–SEVERAL: investment, 202111 financing round Series A $40m led by Qiming Venture Partners 2021-11-24
Relief Therapeutics–BioXcel: AI-based drug discovery, 202111– strategic collab €na using AlphaMeld platform of InveniAI for drug discovery 2021-11-24
BeiGene–SEVERAL: investment, 202111– China mainland IPO in Renminbi with 115m+17.26m RMB shares on START Market of Shanghai Stock Exchange 2021-11-23
Nykode–Regeneron: investment, 202111 equity investment $20m at a premium of 20% as part of license + collab agreement 2021-11-23
Regeneron–Nykode: therapeutic vaccines, 202111– collab + license agreem $30m upfront + $875m milestones off-the-shelf vaccines for cancer + infections 2021-11-23
Abveris–Twist Bioscience: investment, 202111– acquisition merger $150m in shares with max $10m cash at closing + $40m milestones in shares 2021-11-22
Molecubes–Bruker: investment, 202111 acquisition €na by Bruker 2021-11-19
Axel Semrau–Trajan: investment, 202111 acquisition €19.85m by Trajan Group 2021-11-18
Dicerna Pharmaceuticals–Novo Group: investment, 202111– cash tender offer $38.25/share representing total equity value of $3.3b ANNOUNCED 2021-11-18
Owkin–Sanofi: investment, 202111 equity investment $180m by Sanofi in connection with strategic collaboration 2021-11-18
Sanofi–Owkin: cancer drug RnD, 202111– strategic collaboration with $90m for three years + milestones 2021-11-18
Synthace–Horizon Ventures: investment, 202111 financing round Series C totalling $35m incl existing + co-lead investor Horizon Ventures 2021-11-16
Synthace–SEVERAL: investment, 202111 financing round Series C $35m co-led by Sofinnova Partners + Horizon Ventures 2021-11-16
Synthace–Sofinnova: investment, 202111 financing round Series C totalling $35m incl existing + co-lead investor Sofinnova Partners 2021-11-16
Bruker–Bico: MS-based single cell proteomics, 202111– co-marketing of Cellenion’s cellenONE with timsTOF SCP mass spectrometers 2021-11-15
Thermo Fisher–Bico: MS-based single cell proteomics, 202111– co-marketing Cellenion’s cellenONE + proteoCHIP with Orbitrap MS systems + TMT technology 2021-11-15
1 2 3 ... 52 53 54  next pagenext page



Advertisement

Picture [iito] No Content Marketing 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top